How semaglutide produces weight loss

Semaglutide^[1] produces weight loss through a mechanism that is more central than most people expect. It is not primarily a metabolic drug. It works largely in the brain, suppressing appetite and changing how rewarding food feels. That is why semaglutide produces a degree of weight loss that lifestyle change alone rarely matches, and why the results tend to stop when the drug does.

What semaglutide actually does

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals the pancreas to release insulin, slows gastric emptying, and sends satiety signals to the hypothalamus. Semaglutide mimics that hormone but stays active for roughly a week instead of minutes^[2]. The result is sustained appetite suppression between meals, not just the brief fullness your body normally produces after eating.

A randomised trial by Blundell and colleagues gave participants a standardised breakfast and then measured how much they ate at an unrestricted lunch. Those on semaglutide consumed 1,255 kJ less at that meal compared to placebo and showed a 24% reduction in total daily energy intake^[2]. The drug also shifted food preferences toward lower-fat choices, suggesting the effect goes beyond simple fullness.

The STEP-1 numbers

The STEP-1 trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with obesity and randomised them to semaglutide 2.4 mg once weekly or placebo alongside a lifestyle programme. At 68 weeks, the semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo^[1]. That 12.4 percentage-point gap was the largest mean weight loss seen in a non-surgical obesity trial at that point. Around 50% of semaglutide participants lost 15% or more of their body weight.

Gastrointestinal effects were the dominant adverse event: nausea, vomiting and diarrhoea, typically mild to moderate and most common during dose escalation. About 4.5% of participants stopped semaglutide because of GI events versus 0.8% on placebo. The standard approach to reducing this burden is slow dose titration, starting low and stepping up over several months as the body adjusts.

How the brain responds to GLP-1 receptor activation

GLP-1 receptors are expressed not only in the pancreas and gut but throughout the central nervous system, including in the hypothalamus and in areas that regulate food reward. When semaglutide activates those brain receptors, it reduces what researchers and clinicians call hedonic eating: the drive to eat for pleasure rather than genuine hunger. Participants in appetite trials report fewer food cravings and less preoccupation with food generally^[2]. That reduction in food-related mental activity is frequently described by people using the drug as one of the most noticeable changes.

This central mechanism also explains why semaglutide produces more weight loss than dieting instructions alone. Behavioural advice addresses conscious choices. Semaglutide changes the underlying signal strength of hunger and reward. For a fuller picture of how the drug compares to other agents in the same class, see the semaglutide peptide page, which covers the full STEP and SUSTAIN programme in more detail.

Beyond weight loss: the SELECT cardiovascular finding

In 2023, the SELECT trial reported that semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% in 17,604 adults with obesity or overweight who had established cardiovascular disease but no diabetes^[4]. The hazard ratio was 0.80 (95% CI, 0.72 to 0.90). That was the first large-scale evidence that a GLP-1 drug reduced cardiovascular events in people without diabetes, and it shifted how regulators and prescribers think about the drug's role beyond glycaemic control.

What the drug does not do: permanence

The STEP-1 trial ran an extension phase that followed participants after they stopped semaglutide. Within a year of discontinuation, those who had been on semaglutide regained an average of 11.6 percentage points of the weight they had lost, and most cardiometabolic improvements reversed toward baseline^[3]. The authors concluded that obesity requires ongoing treatment, in the same way hypertension does. Stopping the drug stops the mechanism.

That has practical implications for anyone reading semaglutide success stories. The initial weight loss is real and well-documented. The durability depends on continuing the treatment or on what accompanies it (diet, exercise, and in some cases other medications).

How semaglutide is authorised

The EMA authorised semaglutide for chronic weight management (Wegovy) in January 2022^[5]. The FDA had approved Wegovy in June 2021. Both authorisations are for adults with a BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity. In all jurisdictions we cover, semaglutide is prescription-only. For country-specific status, see the semaglutide regulation pages.

What we do not yet know

Long-horizon data on what happens to people who use semaglutide for five or more years are not yet available. The optimal approach to tapering, the best co-interventions to preserve lean mass during rapid weight loss, and the cleanest way to maintain results after stopping are still being worked out in ongoing research. Paediatric data from STEP TEENS are emerging but not fully settled.

This article covers the mechanism and trial evidence for educational purposes. Decisions about whether semaglutide is appropriate for any individual belong with a clinician who knows that person's history.